CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals announced today that it has launched a Phase 1 study of its synthetic peptide C5 inhibitor, RA101495. The Phase 1 trial is a randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback